GlobeNewswire Inc.··Mesoblast LimitedMesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction
Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval